Tuesday 27 September 2022 - 03:25
In Business 42 Years - Since 1980
Recently, we have been and are currently operating with: (1) staff shortages related to CV19 and other factors, (2) vacations, (3) a significant health burden for one senior staff member, and (4) dedication of substantial internal resources to a major public-service project. This situation is expected to continue through Sunday, September 11. During this time, we have been and expect to continue entering, processing and shipping orders normally for in-stock products. However, non-order-related communications and production of backordered products will be subject to some unusual delays. We apologize very much for this situation and appreciate your understanding.
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
B-2332 Binimetinib, Free Base, >99%
Synonyms : [ARRY438162] [ARRY-162] [MEK162]
Related Terms : [Mektovi]
- Size
- US $
- €
- £
- ¥
- 25 mg
- 49
- 50
- 45
- 7,100
- In stock
- 50 mg
- 72
- 74
- 66
- 10,400
- In stock
- 100 mg
- 112
- 116
- 103
- 16,200
- In stock
- 200 mg
- 189
- 195
- 175
- 27,300
- In stock
- 500 mg
- 339
- 351
- 313
- 48,900
- In stock
- 1 g
- 641
- 664
- 593
- 92,500
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 441.23
- C17H15BrF2N4O3
- [606143-89-9]
Solubility: Soluble in DMSO.
- Binimetinib, also known as MEK162, is a novel, second generation MEK1/2 inhibitor. N-RAS mutant melanoma cultures appeared to be particularly sensitive to binimetinib, which reduced ERK1/2 phosphorylation, induced apoptosis, and significantly reduced clonogenic survival. Thumar, J. et al., "MEK targeting in N-RAS mutated metastatic melanoma." Mol. Cancer 13: 45 (2014).
- Binimetinib induced transient retinopathy with multiple bilateral lesions in some patients with metastatic melanoma. Urner-Bloch, U. et al., "Transient MEK inhibitor-associated retinopathy in metastatic melanoma." Ann. Oncol. 25: 1437-1441 (2014).
- Binimetinib showed some activities in patients with advanced melanoma harboring NRAS or Val600 BRAF mutations in a open-label, non-randomised, phase 2 study. Ascierto, P.A. et al., "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study." Lancet Oncol. 14: 249-256 (2013).
- Other CAS numbers previously assigned to binimetinib, free base, namely 1073666-70-2, 1201685-05-3, and 1417448-81-7, have been deleted by CAS and are no longer in use.
- Binimetinib is the active ingredient in the drug product sold under the trade name Mektovi®. This drug is currently approved in at least one country for use, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. NOTE: THE BINIMETINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT MEKTOVI®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
